Tianeptine Anti-Solvent Crystallization Kinetics for Flowability
Controlled Heptane/Water Anti-Solvent Addition at 15°C: Kinetics to Suppress Needle-Like Tianeptine Crystals
In the synthesis route of tianeptine, the final crystallization step critically determines the powder's downstream processability. Uncontrolled anti-solvent addition often yields needle-like crystals of the metastable polymorph, which exhibit poor flowability and low bulk density. Our manufacturing process at NINGBO INNO PHARMCHEM CO.,LTD. employs a precisely controlled heptane/water anti-solvent system at 15°C to kinetically favor the growth of equant, prismatic crystals of the stable form. By maintaining a low supersaturation ratio through slow addition rates (typically 10–30 mL/hr), we suppress the nucleation of the needle-like form II, which is kinetically favored at high local supersaturations. This approach is grounded in the principles of solution-mediated polymorphic transformation (SMPT), where the metastable needles dissolve and reprecipitate as the thermodynamically stable form III. Our field experience shows that even a 2°C deviation from the 15°C setpoint can shift the crystal aspect ratio from 1:1.5 to 1:4, drastically reducing flowability. We monitor the crystallization using in-situ imaging to ensure batch-to-batch consistency. This kinetic control is essential for producing tianeptine with the morphology required for reliable solid-dosage form manufacturing.
Supersaturation Ratio Impact on Tianeptine Bulk Density and Flowability: Bridging Lab Data to IBC Handling
The supersaturation ratio during anti-solvent addition directly dictates the crystal size distribution and, consequently, the powder's bulk density and flowability. In our process, we target a supersaturation ratio of 1.2–1.5, achieved by adding the anti-solvent mixture at a controlled rate to a tianeptine solution in a suitable solvent. This yields a median particle size (D50) of 150–250 µm and a bulk density of 0.45–0.55 g/mL. These parameters are critical for efficient IBC (Intermediate Bulk Container) handling, as powders with lower bulk density or high fines content tend to bridge and rat-hole during discharge. We have observed that when the supersaturation ratio exceeds 1.8, the product contains a significant fraction of fine needles (D10 < 50 µm), reducing the angle of repose from an acceptable 35° to over 45°, which is problematic for automated filling lines. Our technical team can provide batch-specific COA data including particle size distribution and bulk density to ensure compatibility with your handling equipment. For a deeper understanding of how our manufacturing process achieves industrial purity, refer to our detailed analysis of the industrial purity tianeptine synthesis route.
Trace Water in Mother Liquor: Mechanism of Caking During Transit and Mitigation via COA Parameters
A non-standard parameter that often goes unnoticed is the residual water content in the mother liquor after anti-solvent crystallization. Even after filtration and drying, trace amounts of water (above 0.5% w/w) can lead to caking during transit, especially under the pressure and temperature fluctuations in shipping containers. The mechanism involves partial dissolution of fine crystal contacts and subsequent recrystallization, forming solid bridges between particles. This is particularly problematic for tianeptine because the molecule's carboxylic acid group can form hydrates. Our drying protocol reduces residual water to below 0.2% as verified by Karl Fischer titration on every batch COA. Additionally, we recommend packaging in double-lined 210L drums with desiccant bags for long-term storage. This attention to detail ensures that the product arrives at your facility with the same flowability as when it left our plant. For current market insights and bulk pricing, you may find our analysis of tianeptine bulk price 2026 COA useful.
Drop-in Replacement Strategy: Matching Tianeptine Crystal Morphology Without REACH Claims
For procurement managers seeking a reliable second source, our tianeptine is engineered as a drop-in replacement for existing qualified suppliers. We match the crystal morphology—equant, prismatic crystals of the stable polymorph—and particle size distribution to ensure seamless integration into your formulation process. Our product exhibits identical dissolution profiles and compressibility characteristics. We do not make any claims regarding EU REACH compliance or environmental certifications; our focus is on delivering a chemically and physically equivalent product with a robust supply chain. By controlling the anti-solvent crystallization kinetics, we consistently produce tianeptine with a tapped density of 0.55–0.65 g/mL and an angle of repose below 35°, matching the specifications of leading global manufacturers. This strategy minimizes the need for process revalidation, saving time and resources.
Bulk Packaging and Logistics: 210L Drum and IBC Specifications for Anti-Solvent Crystallized Tianeptine
Our tianeptine is packaged in UN-approved 210L HDPE drums with double PE liners, each containing 25 kg net weight. For larger quantities, we offer 500 kg IBCs with similar moisture-barrier liners. The packaging is designed to maintain the product's flowability and prevent caking during transit. We have validated that our anti-solvent crystallized tianeptine withstands the vibration and pressure of sea freight without significant particle attrition. Each shipment includes a batch-specific COA detailing purity (HPLC), residual solvents, water content, and particle size distribution. Please refer to the batch-specific COA for exact numerical specifications. Our logistics team can arrange air, sea, or land freight from our Ningbo facility, with typical lead times of 2–4 weeks depending on destination.
| Parameter | Specification (Typical) | Method |
|---|---|---|
| Purity (HPLC) | ≥ 99.5% | In-house |
| Residual Solvents | Class 3, < 0.5% | GC |
| Water Content (KF) | ≤ 0.2% | Karl Fischer |
| Bulk Density | 0.45–0.55 g/mL | USP <616> |
| Angle of Repose | ≤ 35° | Fixed Funnel |
| Particle Size (D50) | 150–250 µm | Laser Diffraction |
Frequently Asked Questions
What is the optimal cooling ramp for tianeptine anti-solvent crystallization?
Our process uses isothermal anti-solvent addition at 15°C without a cooling ramp. This avoids thermal gradients that can induce secondary nucleation of fine particles. If cooling is required for your process, a linear ramp of 0.5°C/min from 40°C to 15°C is recommended to maintain supersaturation control.
How do I select the best anti-solvent for tianeptine crystallization?
The choice depends on the desired crystal morphology. Heptane/water mixtures (9:1 v/v) are effective for producing prismatic crystals. Pure water can cause excessive local supersaturation and needle formation. The anti-solvent should be miscible with the solvent and have low solubility for tianeptine.
How do you measure the angle of repose for bulk powder handling?
We use the fixed funnel method according to USP <1174>. A sample is poured through a funnel at a fixed height, and the angle of the resulting cone is measured. Values below 35° indicate good flowability suitable for automated filling and IBC discharge.
Can you provide tianeptine with a specific particle size distribution?
Yes, we can tailor the D50 within a range of 100–300 µm by adjusting the anti-solvent addition rate and agitation speed. Please discuss your requirements with our technical team.
What is the shelf life of your tianeptine?
When stored in unopened original packaging at 2–8°C and protected from moisture, the product is stable for 24 months. Retest dates are provided on the COA.
Sourcing and Technical Support
NINGBO INNO PHARMCHEM CO.,LTD. is a global manufacturer of high-purity tianeptine, with a focus on consistent crystal morphology for optimal flowability. Our anti-solvent crystallization process is designed to meet the rigorous demands of pharmaceutical production. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.